Net Profit Margin: 7.58%
Is the net profit margin high or low?
The net profit margin of 7.58% is 23% below its 5-year average of 9.82%, around the middle of its 5-year range (3.94%–13.54%).
As of Monday, June 29, 2026. 9.11% below its 12-month average of 8.34%.
GEHC Profit Margin
Reported quarterly profit margin; no daily interpolation.
GEHC Average Net Profit Margin Chart
GEHC Current vs Average Net Profit Margin Chart
GEHC Net Profit Margin Metrics
NET PROFIT MARGIN
7.58%
NET PROFIT MARGIN AVG TTM
8.34%
NET PROFIT MARGIN AVG 3Y
8.77%
NET PROFIT MARGIN AVG 5Y
9.82%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-9.11%
CURRENT VS 3Y AVG
-13.53%
CURRENT VS 5Y AVG
-22.83%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
GEHC Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| GE HealthCare Technologies Inc. (GEHC) | $29.91B | 7.58% | 8.34% | 8.77% | 9.82% |
| ResMed Inc. (RMD)vs › | $29.05B | 27.44% | 24.50% | 23.01% | 21.32% |
| Zoetis Inc. (ZTS)vs › | $31.88B | 27.79% | 27.55% | 27.17% | 26.57% |
| Biogen Inc. (BIIB)vs › | $31.89B | 13.92% | 15.03% | 17.95% | 19.29% |
| IQVIA Holdings Inc. (IQV)vs › | $31.90B | 8.33% | 8.63% | 8.47% | 7.22% |
| Veeva Systems Inc. (VEEV)vs › | $27.84B | 28.37% | 27.22% | 24.83% | 24.72% |
| Centene Corp. (CNC)vs › | $32.44B | -3.25% | -0.70% | 0.29% | 0.65% |
| DexCom, Inc. (DXCM)vs › | $27.07B | 19.31% | 16.12% | 14.73% | 15.57% |
| Medline Inc. (MDLN)vs › | $32.87B | 3.31% | 4.39% | 2.42% | 2.42% |
| Moderna, Inc. (MRNA)vs › | $26.69B | -143.55% | -128.24% | -70.25% | -50.87% |
Margin Comparison
Operating Margin
12.5%
Net Profit Margin
7.6%
Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Net Profit Margin FAQ
- What is the net profit margin for GE HealthCare Technologies Inc. (GEHC)?
- The net profit margin for GEHC stock is 7.58%.
- Is GE HealthCare Technologies Inc.'s net profit margin high or low?
- The net profit margin of 7.58% is 23% below its 5-year average of 9.82%, around the middle of its 5-year range (3.94%–13.54%).
- What is the TTM average net profit margin for GE HealthCare Technologies Inc. (GEHC)?
- The TTM average net profit margin for GEHC stock is 8.34%.
- What is the 3Y average net profit margin for GE HealthCare Technologies Inc. (GEHC)?
- The 3Y average net profit margin for GEHC stock is 8.77%.
- What is the 5Y average net profit margin for GE HealthCare Technologies Inc. (GEHC)?
- The 5Y average net profit margin for GEHC stock is 9.82%.
GEHC Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-03-31 | 7.58% |
| 2025-12-31 | 3.94% |
| 2025-09-30 | 8.67% |
| 2025-06-30 | 9.71% |
| 2025-03-31 | 11.81% |
| 2024-12-31 | 13.54% |
| 2024-09-30 | 9.69% |
| 2024-06-30 | 8.84% |
| 2024-03-31 | 8.04% |
| 2023-12-31 | 7.74% |
| 2023-09-30 | 7.78% |
| 2023-06-30 | 8.68% |
| 2023-03-31 | 7.90% |
| 2022-12-31 | 11.22% |
| 2022-09-30 | 10.66% |
| 2022-06-30 | 10.82% |
| 2022-03-31 | 8.96% |
| 2021-12-31 | 12.29% |
| 2021-09-30 | 11.71% |
| 2021-06-30 | 13.37% |
| 2021-03-31 | 13.37% |
Related Metrics
About GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Peter J. Arduini